After Stephen Harrison shares key elements from two of his resmetirom presentations at #ILC2022, Jörn Schattenberg, Mazen Noureddin and Michelle Long share thoughts and questions about the presentation. After this, Jörn Schattenberg shares key points from his presentation of an assessment of accuracy of FIB-4 in 2,000 biopsy-confirmed patients in the resmetirom trials.
Stephen Harrison leads a panel including the regular Surfers, Mazen Noureddin and Michelle Long through key elements of his presentation of the Phase 3 MAESTRO NAFLD-1 study at #ILC2022. He also shares information about an analysis of cirrhotic patients in the open-label cohort of the study.
Michelle Long and Mazen Noureddin join the Surfers (including Stephen Harrison) for a wrap-up of the major stories of #ILC2022. Much of the episode focuses on NASH Drug Development, with side conversations about the value and challenges of relying on FIB-4 or, even worse, ALT in patient screening and diagnosis.
Louise Campbell and Robert Mitchell-Thain discuss the world of NAFLD patients both in interacting with clinicians and in living their daily lives
From our #ILC2022 wrap-up episodes, Louise Campbell and Robert Mitchell-Thain discuss the role of NAFLD nurses as communicators delivering pivotal messages to patients, particularly when those messages involve social or person stigma.
Last week, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first major hepatology Congress to be held in person since the start of the pandemic (smaller, but very valuable, meetings like NASH-TAG, LiverCONNECT and Paris NASH have taken place with an in-person component, but the International Liver Congress and The Liver Meeting have not).
Michelle Long and Zobair Younossi join the Surfers to discuss the first three days of #ILC2022.
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green identify some of what they believe will be key papers at #ILC2022. This conversation focuses largely on OS025 Non-invasive fibrosis scores as prognostic biomarkers of liver events, cardiovascular events and all-cause mortality in people with obesity and/or type 2 diabetes in the UK: a longitudinal cohort study.
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green identify some of what they believe will be key papers at 3ILC2022. This conversation focuses on the impact of NAFLD on quality of life.
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green identify some of what they believe will be key papers at 3ILC2022. This conversation focuses on OS 097, which uses LITMUS Metacohort Data to identify the biomarkers that predict each of the four element of the NASH score best and FRI094, a study that evaluates the cost of community-based NAFLD screening for Type 2 Diabetes patients.
